BIOA B Stock Overview
Develops biological drugs for patients with disorders of the central nervous system in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BioArctic AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 182.00 |
| 52 Week High | SEK 318.60 |
| 52 Week Low | SEK 142.90 |
| Beta | -0.19 |
| 11 Month Change | 15.41% |
| 3 Month Change | -16.74% |
| 1 Year Change | -40.60% |
| 33 Year Change | 26.39% |
| 5 Year Change | 191.67% |
| Change since IPO | 527.59% |
Recent News & Updates
BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Sep 01
Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024
Aug 15Recent updates
BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Sep 01Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024
Aug 15Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)
Apr 13News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 19News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 03Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues
Dec 23With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case
Nov 12BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be
Jul 21Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results
Jul 15New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)
Jul 07Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade
May 06Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth
Mar 13Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher
Nov 30We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn
Sep 16We're Interested To See How BioArctic (STO:BIOA B) Uses Its Cash Hoard To Grow
Apr 04We Think BioArctic (STO:BIOA B) Can Easily Afford To Drive Business Growth
Dec 05BioArctic AB (publ) (STO:BIOA B) Shares Could Be 42% Below Their Intrinsic Value Estimate
Sep 15BioArctic (STO:BIOA B) Is In A Strong Position To Grow Its Business
Aug 23Shareholder Returns
| BIOA B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 10.9% | -1.3% | -3.7% |
| 1Y | -40.6% | 28.1% | 14.7% |
Return vs Industry: BIOA B underperformed the Swedish Biotechs industry which returned 28.1% over the past year.
Return vs Market: BIOA B underperformed the Swedish Market which returned 14.7% over the past year.
Price Volatility
| BIOA B volatility | |
|---|---|
| BIOA B Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: BIOA B's share price has been volatile over the past 3 months.
Volatility Over Time: BIOA B's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 96 | Gunilla Osswald | www.bioarctic.se |
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain.
BioArctic AB (publ) Fundamentals Summary
| BIOA B fundamental statistics | |
|---|---|
| Market cap | SEK 16.08b |
| Earnings (TTM) | -SEK 88.28m |
| Revenue (TTM) | SEK 299.35m |
53.7x
P/S Ratio-182.1x
P/E RatioIs BIOA B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOA B income statement (TTM) | |
|---|---|
| Revenue | SEK 299.35m |
| Cost of Revenue | SEK 82.67m |
| Gross Profit | SEK 216.68m |
| Other Expenses | SEK 304.96m |
| Earnings | -SEK 88.28m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 14, 2024
| Earnings per share (EPS) | -1.00 |
| Gross Margin | 72.38% |
| Net Profit Margin | -29.49% |
| Debt/Equity Ratio | 0% |
How did BIOA B perform over the long term?
See historical performance and comparison